Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · CalciMedica, Inc. (CALC)

CalciMedica Q3 net loss narrows to $1.7 million, helped by $3.1 million noncash gain

Positive Impact 3 of 5 earnings

CalciMedica reported third-quarter 2026 results, with a net loss of $1.7 million, or $0.24 per share, versus a net loss of $7.8 million, or $2.59 per share, a year earlier. The improvement was driven mainly by a noncash $3.1 million gain in other income, while operating expenses fell, and the filing reports cash of $13.8 million as of September 30, 2026, which the company expects to fund its operating plan into the second half of 2027.

Key points

  • Q3 2026 net loss was $1.7 million ($0.24 per share), compared with $7.8 million ($2.59 per share) in Q3 2025.
  • Q3 2026 total other income was $3.1 million, mainly from a noncash change in fair value of financial instruments.
  • Q3 2026 research and development expenses were $2.3 million, down from $3.9 million, and general and administrative expenses were $2.4 million, up from $1.8 million.
  • Cash, cash equivalents and short-term investments were $13.8 million as of September 30, 2026.

The filing

CompanyCalciMedica, Inc. (CALC)
Form8-K, current report
Filed with the SECNov 10, 2026, 7:15 AM ET
Accession number0001193125-26-454430

Items reported: 2.02 Results of Operations

Read the filing on SEC.gov ↗

Written by AI on Nov 10, 2026, 7:19 AM ET, from this filing only.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.